89 results about "Deoxyguanosine" patented technology

Oligonucleotide analogues are provided that incorporate 5-aza-cytosine in the oligonucleotide sequence, e.g., in the form of 5-aza-2′-deoxycytidine (decitabine) or 5-aza-cytidine. In particular, oligonucleotide analogues rich in decitabine-deoxyguanosine islets (DpG and GpD) are provided to target the CpG islets in the human genome, especially in the promoter regions of genes susceptible to aberrant hypermethylation. Such analogues can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position. Methods for synthesizing these oligonucleotide analogues and for modulating nucleic acid methylation are provided. Also provided are phosphoramidite building blocks for synthesizing the oligonucleotide analogues, methods for synthesizing, formulating and administering these compounds or compositions to treat conditions, such as cancer and hematological disorders.

Enhancement of T-cell proliferation in a host inhibition is provided by administering 2'-deoxyguanosine and / or prodrug thereof and a PNP inhibitor. The PNP inhibitor has a Ki value of 50 nanomoles or less.

The invention discloses a method for quantitatively detecting the activity of 8-OhdG (8-hydroxy-2'-deoxyguanosine) based on an aniline deposited electrochemical sensing electrode. The method comprises the following steps of preparing a DNA (Deoxyribonucleic Acid) tetrahedral structure with sulfhydryl; modifying, on a gold electrode, the DNA tetrahedral structure with the sulfhydryl to obtain an electrode of which the top end is connected with an 8-OhdG aptamer and which has the DNA tetrahedral structure with the sulfhydryl; forming a G-quadplex electrode; forming a polyaniline deposited electrochemical sensing electrode; detecting a generated current signal of polyaniline by utilizing an electrochemical method, so as to detect the activity of the 8-OhdG. By using the method for quantitatively detecting the activity of the 8-OhdG based on the aniline deposited electrochemical sensing electrode, the detection sensitivity on the 8-OhdG is greatly improved. In compassion with a conventional electrochemical detection method using a reduction peak of the 8-OhdG as a signal, the detection limit is decreased by two orders of magnitude. By using the method for quantitatively detecting the activity of the 8-OhdG based on the aniline deposited electrochemical sensing electrode, the preparation of a complicated material and a DNA labeling probe is not needed; the defects that the preparation of the material and the DNA labeling probe causes that the detection cost is high, the operation is fussy and the reproducibility is poor can be avoided. The method for quantitatively detecting the activity of the 8-OhdG based on the aniline deposited electrochemical sensing electrode has the advantages of being low in cost, being quick, simple and convenient, and being high in sensitivity.

The invention relates to a serum-free culture medium for mesenchymal stem cells and application thereof. The serum-free culture medium comprises a basal culture medium and additive components. The additive components comprise the following components: 2'-Deoxyadenosine, 2'-Deoxycytidine-HCl, 2'-Deoxyguanosine, L-glutamine, human serum albumin, recombinant human transferrin, recombinant human insulin, rhPDGF-BB, rhFGF-b, rhTGF-beta1, rhEGF, sodium selenate and hydrocortisone. The serum-free culture medium disclosed by the invention does not contain animal-derived heterologous component such asbovine serum, and can effectively replace serum to culture bone marrow mesenchymal stem cells; and due to the synergistic effect of the additive components, the culture medium has the advantages of shortening cell cycle, rapid proliferation and good cell consistency while culturing bone marrow mesenchymal stem cells, and can effectively maintain the molecular characteristics and differentiation potential of the bone marrow mesenchymal stem cells. The bone marrow mesenchymal stem cells obtained by the culture medium are suitable for further scientific research and clinical application research.

The invention provides supramolecular nucleoside hydrogel and a preparation method and application thereof, and belongs to the field of biomedical materials. In a powder X-ray diffraction pattern of the hydrogel, diffraction peaks exist at 2theta diffraction angles of 26.7 degrees, 28.4 degrees and 40.5 degrees. The supramolecular hydrogel based on D-configuration alpha-deoxyguanosine is successfully constructed, the alpha-dG hydrogel has excellent stability and cannot be disintegrated and damaged after being placed for 18 months, and the problem that in the prior art, supramolecular hydrogel formed by D-type guanosine is poor in stability is solved. Besides, the alpha-dG hydrogel has good injectability, biocompatibility and drug delivery capacity, can be used as a drug carrier, and is expected to be further applied in the field of biomedicine, such as local treatment of oral mucosa diseases.

T-cell inhibition proliferation in a mammalian host by administering effective amounts of 2'-deoxyguanosine and / or prodrugs thereof; and certain PNP inhibitors.

This invention relates to methods of treating or preventing hemorrhagic and septic shock in an animal by administering inosine, guanosine, deoxyinosine, deoxyguanosine or a mixture thereof. Other purine nucleosides or analogs are described that have therapeutic use in treating or preventing shock. The invention also describes methods for increasing Na / K ATPase activity in erythrocytes or other cells in an animal having below normal activity of this enzyme by administering inosine, guanosine, deoxyinosine, deoxyguanosine or a mixture thereof.

The invention discloses a preparation method of intermediate 2'-deoxyguanosine. A novel recombinant strain of N-nucleoside desoxyribose transferase is constructed, recombinant N-nucleoside desoxyribose transferase is synthesized through self-induction expression, a substrate is added in a dry powder feeding manner, 2'-deoxyguanosine is efficiently prepared with a biological catalysis method, the yield of prepared 2'-deoxyguanosine is high, and the cost is low.

The present invention relates to a hybridoma producing an anti-methylated DNA antibody, obtained by cell fusion of an antibody-producing cell obtained from an animal immunized with an antigen containing 5′-(5-methyl-2′-deoxycytidine-3′-phospho)-2′-deoxyguanosine 3′-phosphate with a myeloma cell. The present invention also relates to a monoclonal antibody produced by the hybridoma and a method for immunoprecipitation of a methylated DNA using the antibody.

The invention discloses an anti-tumor drug prepared from combination of deoxyadenosine with other nucleosides or bases and a preparation method and application thereof. The deoxyadenosine includes deoxyadenosine and deoxyguanosine; the other nucleotides and bases include: deoxycytidine, thymidine, adenosine, guanosine, cytidine, uridine, adenine, guanine, cytosine, uracil and thymidine; The invention has the advantages that both the deoxyadenosine and other nucleosides or bases are human normal nucleotides, the drug for treating various common malignancies such as gastric cancer, lung cancer, liver cancer, colon cancer, esophageal cancer, pancreatic cancer, breast cancer and genital system neoplasms is prepared from the combination of deoxyadenosine as a main drug and other nucleotides and bases as auxiliaries, and the drug has features wide spectrum, low toxicity, mechanism novelty and the like in terms of anti-tumor action; the combine drug has lower toxic and side effects than a single drug; anti-tumour effects are more multiplicative; meanwhile drug resistance of tumors can be delayed.

Disclosed are prodrugs of inactivators of O6-alkylguanine-DNA alkyltransferase (AGT). The prodrugs are cleavable by the β-glucuronidase enzyme, which is either administered to the patient or produced by necrotic tumor cells. The prodrugs are represented by the formula A-B-C, wherein A is a glucuronosyl residue linked through its 1-oxygen to the phenyl ring of B; B is a benzyloxycarbonyl group, optionally ring-substituted with one or more electron withdrawing groups; and C is an inactivator of AGT, e.g., a substituted or unsubstituted O6-benzylguanine or O6-benzyl-2′-deoxyguanosine. Also disclosed are additional inactivators of AGT, pharmaceutical compositions comprising an inactivator or prodrug and a pharmaceutically acceptable carrier, and a method of use of the inactivator or prodrug in enhancing the chemotherapeutic treatment of tumor cells in a mammal, e.g., a human, with an antineoplastic alkylating agent that causes cytotoxic lesions at the O6-position of guanine.